The Role of LRRK2 in the Regulation of Monocyte Adhesion to Endothelial Cells

Journal of Molecular Neuroscience

Volumn 55, Issue 1, 2015, Pages 233-239

  Hongge, Li ^a   Kexin, Guo ^a   Xiaojie, Mou ^a   Nian, Xiong ^a   Jinsha, Huang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Leucine rich repeat kinase 2 (LRRK2); Monocyte adhesion; Nuclear factor B (NF B); Vascular inflammation; VCAM 1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; VASCULAR CELL ADHESION MOLECULE 1;

CELL ADHESION; DRUG EFFECTS; GENETICS; HUMAN; INFLAMMATION; METABOLISM; MONOCYTE; MUTATION; PHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL ADHESION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MONOCYTES; MUTATION; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84939885719     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-014-0312-9     Document Type: Article

References (24)

1. Bosgraaf L, Van Haastert PJ (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643:5–10
2. Dächsel JC, Farrer MJ (2010) LRRK2 and Parkinson disease. Arch Neurol 67:542–547
3. Farkas E, De Jong GI, de Vos RA, Jansen Steur EN, Luiten PG (2000) Pathological features of cerebral cortical capillaries are doubled in Alzheimer’s disease and Parkinson’s disease. Acta Neuropathol 100:395–402
4. Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ, Podolsky DK (2010) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 185(9):5577–5585
5. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G (2000) Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 902:230–239, discussion 239–240
6. Greggio E, Cookson MR (2009) Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions. ASN Neurol 1:e00002
7. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG (2007) The Parkinson’s disease associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313:3658–3670
8. Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, Philpott DJ, Schlossmacher MG (2011) Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 118:795–808
9. Healy DG et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case–control study. Lancet Neurol 7:583–590
10. Kortekaas R, Lenders KL, van Oostrom JCH et al (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57:176–179
11. Martin I et al (2011) Recent advances in the genetics of Parkinson’s disease. Annu Rev Genomics Hum Genet 12:301–325
12. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32(5):1602–1611
13. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson’s disease. Neuroscience 211:13–16
14. Mogi M, Kondo T, Mizuno Y, Nagatsu T (2007) p53 protein, interferon-c, and NF-kB levels are elevated in the parkinsonian brain. Neurosci Lett 414:94–97
15. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des 11:999–1016
16. Sheng B, Wang X, Su B, Lee HG, Casadesus G et al (2012) Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem 120(3):419–429
17. Shi H, Sheng B, Zhang F (2013) Kruppel-like factor 2 protects against ischemic stroke by regulating endothelial blood brain barrier function. Am J Physiol Heart Circ Physiol 304(6):H796–H805
18. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231–1233
19. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301–314
20. Thevenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ (2011) Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One 6:e21519
21. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102(46):16842–16847
22. Zhou G, Hamik A, Nayak L et al (2012) Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. J Clin Invest 122(12):4727–4731
23. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004a) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601–607
24. Zimprich A et al (2004b) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607